JP2010516708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516708A5 JP2010516708A5 JP2009546582A JP2009546582A JP2010516708A5 JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5 JP 2009546582 A JP2009546582 A JP 2009546582A JP 2009546582 A JP2009546582 A JP 2009546582A JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 31
- 230000000975 bioactive effect Effects 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 230000002950 deficient Effects 0.000 claims description 20
- 210000004408 hybridoma Anatomy 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 12
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 12
- 201000010881 cervical cancer Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 9
- 230000009401 metastasis Effects 0.000 claims description 9
- 229940127121 immunoconjugate Drugs 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 201000003163 breast adenoma Diseases 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- 230000025084 cell cycle arrest Effects 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 230000006882 induction of apoptosis Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000007718 nuclear exclusion Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 56
- 210000003462 vein Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 description 58
- 238000001990 intravenous administration Methods 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89701207P | 2007-01-22 | 2007-01-22 | |
| PCT/US2008/051734 WO2008091911A2 (en) | 2007-01-22 | 2008-01-22 | Use of antibody conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516708A JP2010516708A (ja) | 2010-05-20 |
| JP2010516708A5 true JP2010516708A5 (Direct) | 2012-03-01 |
Family
ID=39645132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009546582A Pending JP2010516708A (ja) | 2007-01-22 | 2008-01-22 | 抗体結合体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100143358A1 (Direct) |
| EP (1) | EP2109625A4 (Direct) |
| JP (1) | JP2010516708A (Direct) |
| AU (1) | AU2008207948A1 (Direct) |
| CA (1) | CA2676234A1 (Direct) |
| WO (1) | WO2008091911A2 (Direct) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9539327B2 (en) * | 2007-11-26 | 2017-01-10 | The Research Foundation For The State University Of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| WO2010044894A1 (en) | 2008-10-15 | 2010-04-22 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotonic dystrophy |
| AU2010253863B2 (en) | 2009-05-28 | 2016-01-28 | The United States Government As Represented By The Department Of Veterans Affairs | Amino acid sequences which enhance peptide conjugate solubility |
| WO2010148010A1 (en) | 2009-06-15 | 2010-12-23 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
| JP6178785B2 (ja) * | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用 |
| AU2012240002B2 (en) * | 2011-04-07 | 2017-02-23 | Memorial Sloan-Kettering Cancer Center | Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer |
| CA2907072A1 (en) | 2012-03-16 | 2013-09-19 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of dmpk |
| US12195550B2 (en) * | 2012-03-30 | 2025-01-14 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US20150152170A1 (en) * | 2012-05-23 | 2015-06-04 | Valerion Therapeutics, Llc | Methods for increasing muscle contractility |
| EP2981551B1 (en) | 2013-02-20 | 2020-06-03 | Valerion Therapeutics, LLC | Methods and compositions for treatment of pompe disease |
| US10221250B2 (en) | 2014-01-13 | 2019-03-05 | Valerion Therapeutics, Llc | Internalizing moieties |
| WO2015134607A1 (en) | 2014-03-04 | 2015-09-11 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations |
| US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
| AU2015308894A1 (en) | 2014-08-27 | 2017-03-23 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
| RU2718499C2 (ru) | 2015-10-08 | 2020-04-08 | Юниверсити Оф Юта Рисеч Фаундейшн | Способы и композиции для предупреждения или лечения злокачественной опухоли |
| WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
| JP2019518040A (ja) | 2016-06-15 | 2019-06-27 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 腫瘍に対して標的化されるナノキャリアの抗体媒介性自触反応的送達 |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| CN111316099A (zh) | 2017-07-12 | 2020-06-19 | 约翰霍普金斯大学 | 用于1型糖尿病诊断的基于脂蛋白体的znt8自身抗原 |
| US12304970B2 (en) | 2018-02-01 | 2025-05-20 | Yale University | Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus |
| US12239720B2 (en) | 2018-04-06 | 2025-03-04 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
| WO2020037174A1 (en) | 2018-08-16 | 2020-02-20 | The Johns Hopkins University | Antibodies to human znt8 |
| MX2021002265A (es) | 2018-08-31 | 2021-05-27 | Univ Yale | Composiciones y métodos para aumentar la edición genética basada en oligonucleótidos de donador. |
| AU2020336992A1 (en) | 2019-08-30 | 2022-04-14 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| US12366570B2 (en) | 2019-10-01 | 2025-07-22 | The Johns Hopkins University | Cell-based ZNT8 assay |
| AU2022328714A1 (en) * | 2021-08-20 | 2024-02-29 | The Johns Hopkins University | Cell-surface antibody to a specific biomarker of pancreatic beta-cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4812397A (en) * | 1987-02-10 | 1989-03-14 | The Regents Of The University Of California | MAB-anti-DNA related to nephritis |
| CA2248233A1 (en) * | 1996-03-08 | 1997-09-12 | The Regents Of The University Of California | Delivery system using mab 3e10 and mutants and/or functional fragments thereof |
| WO2001019393A1 (en) * | 1999-09-13 | 2001-03-22 | Cornell Research Foundation, Inc. | Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems |
-
2008
- 2008-01-22 WO PCT/US2008/051734 patent/WO2008091911A2/en not_active Ceased
- 2008-01-22 JP JP2009546582A patent/JP2010516708A/ja active Pending
- 2008-01-22 EP EP08713907A patent/EP2109625A4/en not_active Withdrawn
- 2008-01-22 US US12/523,438 patent/US20100143358A1/en not_active Abandoned
- 2008-01-22 CA CA002676234A patent/CA2676234A1/en not_active Abandoned
- 2008-01-22 AU AU2008207948A patent/AU2008207948A1/en not_active Abandoned
-
2016
- 2016-09-15 US US15/266,919 patent/US20170096497A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516708A5 (Direct) | ||
| JP2021106617A5 (Direct) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| CA2747064C (en) | Monoclonal antibodies directed against lg4/5 domain of alpha3 chain of human laminin-5 | |
| RU2018114904A (ru) | Антитело против garp | |
| JP2016533721A5 (Direct) | ||
| JP2014158469A5 (Direct) | ||
| RU2009149205A (ru) | Моноклональные антитела против клаудина-18 для лечения рака | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| RU2008125324A (ru) | Моноклональные антитела к клаудину-18 для лечения рака | |
| SI2342234T1 (en) | MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| JP2019205480A5 (Direct) | ||
| JP2010509931A5 (Direct) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2019513410A5 (Direct) | ||
| TW201713700A (zh) | 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途 | |
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JP2018529661A5 (Direct) | ||
| JP2007526891A5 (Direct) | ||
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JP2018513141A5 (Direct) |